Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-28

Nasdaq - After-hours US$ 4.03 = AU 54c.....

Same old traders story I'm afraid. 'Buy the rumour - sell the fact'.

Its frustrating to watch - even for an IMM old timer like me. For a biotech in late stage trials (multiple P2 trials and about to embark on P3 after successful data) our market cap - $500m is woeful. Why is this? $100m in the bank too.

Several other ASX biotechs in the oncology space, at a much earlier clinical stage have a significantly higher MC.

It could be that Lag-3 and efti has taken a very long time to get to this stage of its clinical development and interest is in other up and coming novel treatments?

TBH - I've given up realising any reasonable/significant gain until Big Pharma put their hand in their pocket - if that ever happens of course! Competitive tension has a limit before the elastic snaps....

Totally p'd off - apologies.....